Form 4: Armata Pharmaceuticals CEO Deborah Birx Reports Routine Tax Withholding Transaction

Armata Pharmaceuticals, Inc. CEO Deborah Birx reported the disposition of 13,637 common shares at $2.27 each for tax withholding purposes related to restricted stock units.

Summary

• Deborah Birx, Chief Executive Officer and Director of Armata Pharmaceuticals, Inc. (ARMP), reported a transaction on July 10, 2025.
• The transaction involved the disposition of 13,637 shares of common stock.
• The shares were disposed of at a price of $2.27 per share.
• This disposition was for the purpose of satisfying income tax and withholding obligations in connection with the net settlement of restricted stock units.
• Following this transaction, Deborah Birx beneficially owns 217,377 shares of common stock directly.

Sentiment

Score: 5

Explanation: The transaction is a routine tax withholding event related to equity compensation, which is neutral in terms of company performance or outlook. It reflects the vesting of previously granted restricted stock units.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide broader industry context or trends. It reflects an individual executive's compensation-related share activity rather than strategic industry developments.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes, not a sale for personal liquidity or a change in investment conviction.

Key Dates

Keywords

Armata Pharmaceuticals, ARMP, Deborah Birx, Form 4, Insider Transaction, Tax Withholding, Restricted Stock Units, CEO, Director, Common Stock